Journal Article

Hydroxyethyl Starch 130/0.4 versus Ringer's Acetate in Severe Sepsis

Winding, Robert, Kjældgaard, Anne-Lene, Strand, Kristian, Madsen, Kristian R, Poulsen, Lone M, Winkel, Per, Andersen, Lasse H, Mondrup, Frederik, Møller, Morten H, Haase, Nicolai, Elkjær, Jeanie M, Guttormsen, Anne B, Fabritius, Maria L, Nielsen, Jonas, Klemenzson, Gudmundur, Berezowicz, Pawel, Thornberg, Klaus J, Holst, Lars B, Thormar, Katrin, Quist, Lars, Tenhunen, Jyrki, Bestle, Morten, White, Jonathan O, Åneman, Anders, Søe-Jensen, Peter, Pott, Frank C, Møller, Thea P, Perner, Anders, Bendtsen, Asger, Wiis, Jørgen, Wetterslev, Jørn, Steensen, Morten

2012

Overview

In this study, patients with severe sepsis were assigned to fluid resuscitation with starch (HES 130/0.4) or Ringer's acetate. The starch group had an increased risk of death at day 90 and increased use of renal-replacement therapy, as compared with the Ringer's acetate group. Intravenous fluids are the mainstay of treatment for patients with hypovolemia due to severe sepsis. Colloid solutions are used to obtain rapid and lasting circulatory stabilization, but there are limited data to support this practice. 1 The Surviving Sepsis Campaign guidelines recommend the use of either colloids or crystalloids, 2 but high-molecular-weight hydroxyethyl starch (HES) may cause acute kidney failure in patients with severe sepsis, as observed in two randomized trials. 3 , 4 Those trials had substantial limitations, and participants received HES solutions with a molecular weight of 200 kD and a substitution ratio (the number of hydroxyethyl groups per glucose molecule) of . . .

• Publisher: Massachusetts Medical Society
• Subject: Bacterial diseases / Bacterial sepsis / Biological and medical sciences / General aspects / Human bacterial diseases / Infectious diseases / Medical sciences